Get the Stockscreener App
24.05
0.23%
0.0798
Nurix Therapeutics Inc stock is traded at $24.05, with a volume of 413.17K.
It is up +0.23% in the last 24 hours and up +64.11% over the past month.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
See More
Previous Close:
$23.97
Open:
$23.76
24h Volume:
413.17K
Relative Volume:
0.22
Market Cap:
$2.49B
Revenue:
$71.78M
Net Income/Loss:
$-295.28M
P/E Ratio:
-7.6114
EPS:
-3.1597
Net Cash Flow:
$-271.85M
1W Performance:
+0.73%
1M Performance:
+64.11%
6M Performance:
+37.84%
1Y Performance:
+88.73%
1-Day Range:
$23.11
$24.27
1-Week Range:
$23.11
$24.88
52-Week Range:
$8.195
$24.88
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
24.05 | 2.51B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
528.26 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.63 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.39 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.74 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.28 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline - Yahoo Finance
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade - Yahoo Finance
Pictet Asset Management Holding SA Sells 741,462 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Roche collaborates with Nurix Therapeutics to develop BTK degrader bexobrutideg for cancer and immune diseases - Select Science
Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value - Insider Monkey
Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga
Oppenheimer reiterates Nurix stock rating on BTK degrader potential By Investing.com - Investing.com India
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Nurix Therapeutics, Inc.(NasdaqGM: NRIX) added to Russell 2500 Growth Benchmark - marketscreener.com
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Nurix Therapeutics, Inc.(NasdaqGM: NRIX) added to Russell 2000 Growth Benchmark - marketscreener.com
Nurix Therapeutics, Inc.(NasdaqGM: NRIX) added to Russell 3000E Growth Benchmark - marketscreener.com
Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN
5 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Technical Reactions to NRIX Trends in Macro Strategies - Stock Traders Daily
Is Nurix Therapeutics (NRIX) Overvalued As Its Roche Deal Lifts Hopes For Future Growth? - Sahm
Nurix Stock Up 29% in a Month: Here's What You Should Know - Yahoo Finance
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Roche Mega Deal Sends Nurix Stock Soaring - TipRanks
Strength seen in Nurix Therapeutics (NRIX): Can its 6.8% jump turn into more strength? - MSN
Insider Sell: Gwenn Hansen Sells Shares of Nurix Therapeutics In - GuruFocus
Nurix Therapeutics CLO Christine Ring sells $580,505 in shares By Investing.com - Investing.com Australia
Nurix (NRIX) Climbs to 52-Week High — This Deal May Hold the Answer - Insider Monkey
Form 144 NURIX THERAPEUTICS INC For: 25 June - Investing.com UK
Form 4 Nurix Therapeutics Inc For: 25 June By Investing.com - Investing.com Australia
5 Stocks Winning by Double Digits - Insider Monkey
Nurix therapeutics CSO Gwenn Hansen sells $107,880 in stock - Investing.com
Nurix Therapeutics CLO Christine Ring sells $580,505 in shares - Investing.com
Nurix therapeutics CSO Gwenn Hansen sells $107,880 in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hansen Gwenn - Moomoo
Nurix (NRIX) CSO executes pre-planned sale of 5,394 shares at $20 - Stock Titan
Nurix Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Ring Christine - Moomoo
Form 144 NURIX THERAPEUTICS INC For: 25 June By Investing.com - Investing.com South Africa
NRIX: Director Christine Ring files to sell 28,935 shares (NRIX) - Stock Titan
Nurix Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
NRIX (NASDAQ) filing: 5,394 RSUs to be sold; 3,214 sold on 04/30/2026 - Stock Titan
Nurix Therapeutics, Inc. Actuals & Estimates (NASDAQ:NRIX) - TradingView
Nurix Therapeutics stock hits 52-week high at $22.51 By Investing.com - Investing.com Nigeria
Nurix Therapeutics stock hits 52-week high at $22.51 - Investing.com UK
NRIX Forecast — Price Target — Prediction for 2027 - TradingView
Flax Pond Capital LLC Invests $1.52 Million in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics (NRIX) Q4 2025 earnings summary - Quartr
Nurix Therapeutics Stockanalyst snapshot and weekly review - AD HOC NEWS
Nurix surges 43% on up to $3B cancer drug deal with Roche - MSN
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nurix Therapeutics Inc Stock (NRIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Jul 02 '26 |
Sale |
23.56 |
11,008 |
259,366 |
13,579 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):